The KRAS mutations were present in 34.5% (n=79) of advanced and recurrent CRC patients, including 23.1% (n=53) with codon 12 mutations and 11.4% (n=26) with codon 13 mutations. This evidence concerns the gene KRAS and colorectal carcinoma.